Tara Sutton Elected to Robins Kaplan LLP Executive Board
January 27, 2015
“Tara is a highly esteemed firm partner and we are honored to have her join as the newest member of our Board. Her perspective will be a valuable asset for the direction of our firm,” stated Martin R. Lueck, Chairman of the Executive Board.
Ms. Sutton is a Partner in Robins Kaplan LLP’s Minneapolis office, and serves as Chair of the firm’s Mass Tort practice group. She focuses her trial practice on the representation of individuals who were harmed by the pharmaceutical and medical device industry. Most recently, Ms. Sutton negotiated on behalf of plaintiffs the $1.4 billion global settlement of the Stryker Rejuvenate/ABGII modular hip litigation. She served on the Executive Committee and was lead trial counsel in the Chantix Multi-District Litigation which settled for more than $300 million and acted as Lead Counsel and Lead Trial Counsel in the Mirapex Multi-District Litigation, MDL No. 1836 (D. Minn.), where she obtained a jury verdict of $8.2 million dollars.
Ms. Sutton was named a Profiles in Diversity Journal “Woman Worth Watching” in September 2014, a Law360 “Female Powerbroker” in March 2014 and a “Plaintiff Top 150 Women in Litigation,” by Benchmark Litigation in 2013. She serves on the Board of Governors for the Minneapolis Children’s Theatre and is Treasurer of the Public Justice Foundation, a public-interest law firm dedicated to protecting consumer rights.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.